Insulet Corporation $PODD Holdings Boosted by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI grew its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 138.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 7,880 shares of the medical instruments supplier’s stock after acquiring an additional 4,569 shares during the period. Citizens Financial Group Inc. RI’s holdings in Insulet were worth $1,028,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PODD. Elevation Wealth Partners LLC increased its stake in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares during the last quarter. Activest Wealth Management raised its holdings in Insulet by 186.3% in the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 149 shares in the last quarter. Continuum Advisory LLC acquired a new stake in Insulet in the second quarter valued at $46,000. Sound Income Strategies LLC boosted its stake in Insulet by 4,620.0% during the 1st quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 231 shares during the last quarter. Finally, State of Wyoming boosted its stake in Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after acquiring an additional 73 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Jefferies Financial Group decreased their price objective on shares of Insulet from $275.00 to $190.00 and set a “buy” rating for the company in a report on Monday, October 12th. Oppenheimer lowered shares of Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. TD Cowen reduced their price target on shares of Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Finally, UBS Group decreased their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $186.68.

Insulet Price Performance

Shares of NASDAQ PODD opened at $148.93 on Thursday. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $10.33 billion, a price-to-earnings ratio of 27.84, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. The business has a 50 day simple moving average of $140.84 and a 200-day simple moving average of $181.20.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the prior year, the company posted $1.17 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts expect that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.